Acute Respiratory Viral Infections Research Articles

Clinical and economic assessment of using topical bacterial lysate Imudon® for the treatment and prevention of acute upper respiratory tract infections in children

Objective: pharmacoeconomic analysis of the feasibility of using topical bacterial lysate Imudon® for the treatment and prevention of acute upper respiratory tract infections in the pediatric population in comparison with other medicines belonging to the class of topical antiseptics.Material and methods. For the population calculated on the basis of Rosstat data, taking into account the Russian clinical recommendations "Acute respiratory viral infection (ARVI)" and "Acute tonsillitis and pharyngitis (acute tonsillopharyngitis)", the direct medical costs of medical care were determined. The cost of basic therapy of 1 case of acute respiratory infection (ARI) with symptoms of pharyngitis was calculated for two variants of clinical course: favorable (when ARI proceeds without complications and the patient does not need to be prescribed antibacterial drugs), and unfavorable (when confirmed bacterial infection joins and antibiotics are required). The indirect costs of child care are associated with lost gross domestic product (GDP). In estimating the GDP shortfall, it was assumed that the parent does not contribute to the country’s GDP during the entire childcare period.Results. GDP per capita for 2022 amounted to 2853.13 rubles per day. Thus, with a favorable course of the disease, indirect costs will be 19,972 rubles, and with an unfavorable course – 39,944 rubles. The total costs of the healthcare system and the state for 1 ARI patient are 32,192 rubles in case of favorable course and 71,644 rubles in case of unfavorable course. Imudon® administration allows reducing direct costs of parents for purchase of medicines for treatment of 1 ARI case by 23.6% compared to the therapeutic strategy associated with the use of local antiseptics.Conclusion. For the first time in Russian economic conditions, the use of Imudon® for the treatment and prevention of acute upper respiratory tract infections in children was evaluated. Its use from the first ARI symptoms allows refusing the use of local antiseptics, shortens the duration of the disease symptoms, and reduces the need for antibiotics, i.e. is feasibleable compared to local antiseptics.

Increased Risk of Acute Aortic Events following COVID-19 and Influenza Respiratory Viral Infections

Acute respiratory viral infections have been associated with an increased incidence of adverse cardiovascular events. However, it is unclear whether severe respiratory viral infections are associated with an increased risk of acute aortic syndromes (AAS). This study was designed to assess whether Coronavirus disease 2019 (COVID-19) and Influenza illnesses are associated with an increased incidence of subsequent AAS in the US population. We used the MarketScan database (2011-2021) to identify patients 18-99years of age without prior diagnosis of aortic pathology who were diagnosed with COVID-19 or Influenza. Identified patients were matched 1:1 by age and sex to control patients without COVID-19 or Influenza. The primary outcome was incidence of AAS (dissection, intramural hematoma, penetrating aortic ulcer, or aneurysm rupture) within 180-days of a viral infection. The association between infection and risk of developing an AAS was analyzed using multivariate Cox proportional hazards models. We identified 1,775,698 patients, including 779,229 (44%) with mild COVID-19, 42,141 (2%) with severe COVID-19, and 66,479 (4%) with Influenza that were matched to 887,849 (50%) control patients without COVID-19 or Influenza illnesses. A total of 164 patients experienced AAS within 6-months after diagnosis, which was highest among those after severe COVID-19. The predicted incidence of AAS was significantly higher among patients after severe COVID-19 (14.1 events/100,000 person-years), mild COVID-19 (13.3 events/100,000), and influenza (13.3 events/100,000) when compared to control patients (2.6 events/100,000). In risk-adjusted Cox regression models, severe COVID-19 (HR:5.4, 95% CI:2.8-10.4; P<0.01), mild COVID-19 (HR:5.1, 95% CI:3.3-7.7; P<0.01) and influenza (HR:5.1, 95% CI:2.6-9.7; P<0.01) diagnoses were associated with a significantly increased risk of AAS within 180-days when compared to matched controls. There is an increased risk of developing acute aortic event in the months following illness with Influenza or COVID-19. These data highlight the need to closely monitor at-risk patients following a viral respiratory infection.

COVID-19 Across Pandemic Variant Periods: The Severe Acute Respiratory Infection-Preparedness (SARI-PREP) Study.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has evolved through multiple phases in the United States, with significant differences in patient centered outcomes with improvements in hospital strain, medical countermeasures, and overall understanding of the disease. We describe how patient characteristics changed and care progressed over the various pandemic phases; we also emphasize the need for an ongoing clinical network to improve the understanding of known and novel respiratory viral diseases. To describe how patient characteristics and care evolved across the various COVID-19 pandemic periods in those hospitalized with viral severe acute respiratory infection (SARI). Severe Acute Respiratory Infection-Preparedness (SARI-PREP) is a Centers for Disease Control and Prevention Foundation-funded, Society of Critical Care Medicine Discovery-housed, longitudinal multicenter cohort study of viral pneumonia. We defined SARI patients as those hospitalized with laboratory-confirmed respiratory viral infection and an acute syndrome of fever, cough, and radiographic infiltrates or hypoxemia. We collected patient-level data including demographic characteristics, comorbidities, acute physiologic measures, serum and respiratory specimens, therapeutics, and outcomes. Outcomes were described across four pandemic variant periods based on a SARS-CoV-2 sequenced subsample: pre-Delta, Delta, Omicron BA.1, and Omicron post-BA.1. Multicenter cohort of adult patients admitted to an acute care ward or ICU from seven hospitals representing diverse geographic regions across the United States. Patients with SARI caused by infection with respiratory viruses. Eight hundred seventy-four adult patients with SARI were enrolled at seven study hospitals between March 2020 and April 2023. Most patients (780, 89%) had SARS-CoV-2 infection. Across the COVID-19 cohort, median age was 60 years (interquartile range, 48.0-71.0 yr) and 66% were male. Almost half (430, 49%) of the study population belonged to underserved communities. Most patients (76.5%) were admitted to the ICU, 52.5% received mechanical ventilation, and observed hospital mortality was 25.5%. As the pandemic progressed, we observed decreases in ICU utilization (94% to 58%), hospital length of stay (median, 26.0 to 8.5 d), and hospital mortality (32% to 12%), while the number of comorbid conditions increased. We describe increasing comorbidities but improved outcomes across pandemic variant periods, in the setting of multiple factors, including evolving care delivery, countermeasures, and viral variants. An understanding of patient-level factors may inform treatment options for subsequent variants and future novel pathogens.

Discovery of GS-7682, a Novel 4'-Cyano-Modified C-Nucleoside Prodrug with Broad Activity against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green Monkeys.

Acute respiratory viral infections, such as pneumovirus and respiratory picornavirus infections, exacerbate disease in COPD and asthma patients. A research program targeting respiratory syncytial virus (RSV) led to the discovery of GS-7682 (1), a novel phosphoramidate prodrug of a 4'-CN-4-aza-7,9-dideazaadenosine C-nucleoside GS-646089 (2) with broad antiviral activity against RSV (EC50 = 3-46 nM), human metapneumovirus (EC50 = 210 nM), human rhinovirus (EC50 = 54-61 nM), and enterovirus (EC50 = 83-90 nM). Prodrug optimization for cellular potency and lung cell metabolism identified 5'-methyl [(S)-hydroxy(phenoxy)phosphoryl]-l-alaninate in combination with 2',3'-diisobutyrate promoieties as being optimal for high levels of intracellular triphosphate formation in vitro and in vivo. 1 demonstrated significant reductions of viral loads in the lower respiratory tract of RSV-infected African green monkeys when administered once daily via intratracheal nebulized aerosol. Together, these findings support additional evaluation of 1 and its analogues as potential therapeutics for pneumo- and picornaviruses.

Post-COVID-19 Fungal Infections: A Case Series

Severe acute respiratory syndrome coronavirus 2-like other viral infections cause temporary immunosuppressive effects. This COVID-19 infection-induced temporary suppression of cellular immunity can predispose to infections like fungal. Furthermore, high-dose corticosteroids used in COVID-19 management can trigger or accelerate fungal infections. This case series presents the clinicomicrobiological profile of a few such admitted cases, as it is very important for all clinicians and clinical microbiologists to keep the new yet recently not-so-uncommon entities in mind while evaluating a patient.

Changes in the etiological structure of severe acute respiratory viral infections in children and adults under the influence of the COVID-19 pandemic

Introduction. The traditional surveillance system for influenza and ARVI provides a general description of epidemics, but does not provide information on the age-related characteristics of the etiology and clinical peculiarities of severe acute respiratory diseases (SARI) in hospitalized patients. Aim. To monitor the etiology of SARI in hospitalized children and adults, assessing the impact of the COVID-19 pandemic on this process. Materials and methods. Standardized clinical and laboratory monitoring of SARI among 18,458 hospitalized patients was carried out in hospitals in three cities of Russia with weekly PCR detection of 11 types of pathogens. Results. According to the investigation of hospitalized patients with SARI for the period from 2018 to 2023, the viral etiology of respiratory diseases was deciphered in 58.3% of cases. Weekly monitoring showed a change in the etiological mosaic of SARI pathogens during the SARS-CoV-2 pandemic with a sharp decrease in the frequency of detection of influenza and respiratory syncytial virus (RSV) during the 2020–2021 season against the background of a significant increase of metapneumovirus and rhinovirus infections in children. During the 2022-2023 season an increase in the proportion of RSV infection in children under 6 years of age (up to 36.2%) was noted against the background of a significant decrease in the frequency of SARS-CoV-2. In the intensive care units (ICU), RSV infection was most often in children during the post-pandemic period (up to 30.1–53.6% of positive cases, p 0.001); in adults, SARS-CoV-2 was mostly detected (76,5–100% of cases, p 0.001). Conclusion. Hospital surveillance data significantly complements the epidemiological information obtained in the traditional surveillance system. Monitoring of infections has shown a continuously changing etiological infrastructure of SARI, with the disappearance of influenza and RSV during the COVID-19 pandemic and their return to circulation in the post-pandemic period.

Laboratory indicators of the disorders of immune-endocrine balance in children with acute respiratory viral infection during post-COVID period

Laboratory indicators of the disorders of immune-endocrine balance in children with acute respiratory viral infection during post-COVID period

Comparison of the efficacy of paracetamol and ibuprofen for fever in children under 5 years of age

Fever accounts for a significant proportion of pediatric emergency consultations, with up to 40% of children under the age of five see a doctor for this condition. Fever is usually the result of acute respiratory viral infection, is short-lived and resolves on its own. However, in the hyperergic variant or with depletion of compensatory mechanisms, fever can be the cause of the development of pathological conditions. Therefore, timely and effective control of fever has always been a subject of interest to parents and pediatricians. Current guidelines define fever above 38.5 °C as a condition in which the use of antipyretics is indicated. Paracetamol (acetaminophen) and ibuprofen are the most widely prescribed and available over-the-counter antipyretics in children. Despite the widespread use of these drugs, recommendations for the treatment of young children remain varied, leading to irrational use of antipyretics. Therefore, the aim of this review is to analyze existing clinical trials comparing paracetamol and ibuprofen to develop guidelines for pediatricians on the management of febrile pediatric patients.

The impact of interferon receptor gene polymorphisms on humoral immunity to influenza and frequency of acute respiratory viral infections; taking into account vaccination status

The impact of interferon receptor gene polymorphisms on humoral immunity to influenza and frequency of acute respiratory viral infections; taking into account vaccination status

New medical technologies in cough therapy: results of a double-blind randomized placebo-controlled multicenter clinical trial

To study the efficacy and safety of Eladis® in comparison with placebo in patients with non-productive cough. A phase III clinical trial enrolled 250 patients aged 18-65 years with acute respiratory viral infection with upper respiratory tract involvement or acute bronchitis. Patients were randomized into 2 groups of 125 subjects: group 1 received Eladis® (40 mg tablets), group 2 received a matching placebo. The patients received the study drugs 1 tablet BID for 7-14 days. After the treatment, patients were followed up (day 7±2) to assess the effect of therapy on the frequency of coughing attacks, the frequency and severity of daytime and nocturnal cough, the severity of cough, the duration of clinical cough cure, and the effect on the severity of the main acute respiratory viral infection symptoms. The results of the study demonstrate the overall efficacy and statistically significant superiority of Eladis® over placebo: there were significant differences between the study groups in the proportion of patients who decreased the coughing attack frequency by ≥50% by day 5 (p<0.0001). In addition, the clinical cure of cough in the Eladis® group occurred 2 days earlier: the median time was 6 days, vs 8 days in placebo group. There was a decrease in the frequency of cough attacks and a decrease in its severity by more than 3.5 points by day 5 of treatment. All the effects were associated with high safety of the drug.

Prevalence of non- SARS CoV-2 respiratory virus infection in children during COVID-19 pandemic in Chennai, South India.

Acute respiratory virus infections (ARIs) are a significant cause of morbidity and mortality among children worldwide. Respiratory viral infections in children have been significantly impacted during the COVID-19 pandemic. Variations in the prevalence of respiratory virus infections have been associated with the COVID-19 pandemic, which corresponds to the clinical epidemiology of community-acquired respiratory viruses. The aim of the present study was to investigate the prevalence of acute respiratory viral infection in COVID-19 negative children. The study included 100 SARS-CoV2 negative children with respiratory tract infections. Real-time polymerase chain reaction was used to determine the prevalence of respiratory viruses causing ARI in children. In our study, adenovirus and HRSV-A were predominantly reported in SARS-CoV2 negative children. The results of the study indicated that the incidence of viruses causing acute respiratory tract infections in children changed during the COVID-19 pandemic.

Serum Levels of Arachidonic Acid, Interleukin-6, and C-Reactive Protein as Potential Indicators of Pulmonary Viral Infections: Comparative Analysis of Influenza A, Respiratory Syncytial Virus Infection, and COVID-19.

Acute respiratory tract infections, including influenza A (FluA), respiratory syncytial virus (RSV) infection, and COVID-19, can aggravate to levels requiring hospitalization, increasing morbidity and mortality. Identifying biomarkers for an accurate diagnosis and prognosis of these infections is a clinical need. We performed a cross-sectional study aimed to investigate the changes in circulating levels of arachidonic acid, interleukin 6 (IL-6), and C-reactive protein (CRP) in patients with FluA, RSV, or COVID-19, and to analyze the potential of these parameters as diagnosis or prognosis biomarkers. We analyzed serum samples from 172 FluA, 80 RSV, and 217 COVID-19 patients, and 104 healthy volunteers. Individuals with lung viral diseases showed reduced arachidonic acid concentrations compared to healthy people, with these differences being most pronounced in the order COVID-19 > RSV > FluA. Conversely, IL-6 and CRP levels were elevated across diseases, with IL-6 emerging as the most promising diagnostic biomarker, with areas under the curve (AUC) of the receiver operating characteristics plot higher than 0.85 and surpassing arachidonic acid and CRP. Moreover, IL-6 displayed notable efficacy in distinguishing between FluA patients who survived and those who did not (AUC = 0.80). These findings may provide useful tools for diagnosing and monitoring the severity of acute viral respiratory tract infections, ultimately improving patient outcomes.

Organization and performance indicators of the emergency department in the children's clinic in the city of Ufa

The article presents the work experience and retrospective analysis of the indicators of the emergency department for children of the "Children's Clinic No. 5" in Ufa for 2023. The average number of calls to emergency services was 3491 calls per year. On average, one doctor in the department handles 10–12 calls per day. However, throughout the year there is an uneven load on the emergency department: in the autumn-winter period the frequency of calls increases to 20–30, in the summer months it decreases to 3–5 calls. The overwhelming majority of calls were made by those aged 3–7 years (35% of cases); teenagers sought emergency help least often (6% of cases). The largest percentage of visits was due to hyperthermic syndrome (43% of cases), obstruction of the upper and lower respiratory tract was recorded in second place (21% of cases), and calls related to pain syndrome were in third place (12%). Analysis of the morbidity structure by nosology demonstrated the following results: the leading pathology (70,2% of cases) was acute respiratory viral infection, the second place was occupied by diseases of the gastrointestinal tract (15,5% of cases). Thus the emergency medical care department contributes to the timely and effective provision of emergency care to children at home, prevents the development of decompensation of body functions, reduces the risk of disability and promotes the health of young citizens of the Russian Federation.

EFFECTIVENESS OF SIBERIAN FIR EXTRACT USED AS AN INTERFERON INDUCTOR IN COMPLEX THERAPY OF ACUTE RESPIRATORY VIRAL INFECTIONS

Objective is a study of the effectiveness and safety of using a "Florenta" dietary supplement based on Siberian fir extract as an interferon inducer in the complex therapy of acute respiratory viral infections. Material and methods. The object of the study was a biologically active food supplement based on a concentrated aqueous extract of Siberian fir needles (Abies sibirica L.). The patients under observation were adults with various manifestations of acute respiratory viral infection (ARVI). The pa-tients were matched in age, gender and concomitant pathology. During the study, vital signs were monitored and tolerability and possible adverse events were recorded. The results of laboratory parameters were as-sessed and an overall evaluation of the effectiveness of therapy and patient satisfaction with treatment results was made. Results. It has been established that the Siberian fir extract included into the treatment of patients with mild to moderate ARVI allows managing the clinical symptoms of the disease in a shorter time and increasing the effectiveness of complex therapy. At the same time, the risk of complications is reduced and the prognosis for the disease course becomes positive. The drug under study has been proven to be well tolerated and safe. Analysis of interferon status has revealed a significant improvement in the parameters of interferons under study. Conclusions. As a result of the studies, it has been found out that a biologically active food supplement based on Siberian fir extract as part of com-plex therapy for ARVI reduces the severity and intensity of symptoms of the disease, accelerates the recovery of patients and leads to the normaliza-tion of their interferon status

Exploring the Impact of Antibiotics on Fever Recovery Time and Hospital Stays in Children with Viral Infections: Insights from Advanced Data Analysis.

Background: Antibiotic overuse in pediatric patients with upper respiratory tract infections (UR-TIs) raises concerns about antimicrobial resistance. This study examines the impact of antibiotics on hospital stay duration and fever resolution in pediatric patients diagnosed with viral infections via a multiplex polymerase chain reaction (PCR) respiratory panel. Methods: In the pediatric ward of Imam Abdulrahman Bin Faisal Hospital, a retrospective cohort analysis was conducted on pediatric patients with viral infections confirmed by nasopharyngeal aspirates from October 2016 to December 2021. Cohorts receiving antibiotics versus those not receiving them were balanced using the gradient boosting machine (GBM) technique for propensity score matching. Results: Among 238 patients, human rhinovirus/enterovirus (HRV/EV) was most common (44.5%), followed by respiratory syncytial virus (RSV) (18.1%). Co-infections occurred in 8.4% of cases. Antibiotic administration increased hospital length of stay (LOS) by an average of 2.19 days (p-value: 0.00). Diarrhea reduced LOS by 2.26 days, and higher albumin levels reduced LOS by 0.40 days. Fever and CRP levels had no significant effect on LOS. Time to recovery from fever showed no significant difference between antibiotic-free (Abx0) and antibiotic-received (Abx1) groups (p-value: 0.391), with a hazard ratio of 0.84 (CI: 0.57-1.2). Conclusions: Antibiotics did not expedite recovery but were associated with longer hospital stays in pediatric patients with acute viral respiratory infections. Clinicians should exercise caution in prescribing antibiotics to pediatric patients with confirmed viral infections, especially when non-critical.

Research on the Effectiveness of Using a Combined Medication Containing Quercetin, Vitamins C and D, and Zinc in the Treatment and Prevention of Acute Respiratory Viral Infections

The objective: to evaluate the effectiveness of the combined medication, which includes ascorbic acid (vitamin C), vitamin D3 (cholecalciferol), quercetin, and zinc oxide in the treatment and prevention of complications of acute respiratory viral infections (ARVI) at the outpatient level. Materials and methods. 5,982 patients (42.68% men and 57.32% women) aged 18 years and older with symptoms of ARVI participated in the study. The study was conducted in two stages: 1) diagnosis of ARVI and prescribing treatment, including a combined medication; 2) final assessment of the effectiveness, safety and tolerability of therapy. The total duration of participation in the study for one patient was no more than 1 month. In the complex treatment of ARVI at the outpatient level, according to the instructions, 1, 2 or 3 tablets per day were prescribed, depending on the severity of the course of the disease. The duration of treatment was from 5 to 30 days. 1 tablet of the combined medication includes ascorbic acid (vitamin C) – 100 mg, sodium ascorbate – 450 mg (equivalent to ascorbic acid – 400 mg), vitamin D3 (cholecalciferol) – 1000 IU, quercetin – 250 mg, zinc oxide (equivalent to elemental zinc) – 10 mg. Efficacy was evaluated based on the frequency of bacterial complications of ARVI, which required the antibiotic therapy. The safety of the therapy was assessed by the frequency of adverse outcomes and their severity. Results. The main indication for the use of the combined medication was ARVI (83% of patients) without etiological clarification, 5% of patients were diagnosed with COVID-19 and 11% – influenza. In 6% of patients the drug was prescribed for prophylactic purposes and for non-infectious diseases. Clinical manifestations of acute bronchitis were found in 12% of patients with ARVI, acute sinusitis – in 8% of patients. Bacterial complications (pneumonia, otitis, bacterial sinusitis, and bronchitis) in which there is a need to use systemic antibiotics occurred in 4.79% (95% CI: 4.27–5.35%) of ARVI patients which have received the combined medication. The frequency of prescribing systemic antibiotics increased in proportion to the severity of the disease and the age of the patients. Adverse non-serious, rare side effects when using the combined medication were found in 0.56% of patients who participated in the study. Conclusions. The combined medication, which includes ascorbic acid (vitamin C), vitamin D3 (cholecalciferol), quercetin, zinc oxide, has good tolerance and can be recommended to alleviate the condition of patients with ARVI, prevent complications, shorten the duration of treatment and promote faster recovery of the patient.

Acute respiratory viral infections and influenza in children: before, during, after the COVID-19 pandemic

Acute respiratory viral infections and influenza in children: before, during, after the COVID-19 pandemic

Respiratory viral coinfections in pediatric patients in the primary care setting: a multicenter prospective study within the COPEDICAT network.

Acute respiratory viral infections pose a significant healthcare burden on the pediatric population globally, but data on the dissemination pattern in the community due to the COVID-19 pandemic are scarce. We conducted a two-year prospective multicenter study in Catalonia (Spain) that examined the prevalence and coinfection dynamics of respiratory viruses among 1276 pediatric patients from different age groups attending primary care. Coinfection analysis demonstrated complex patterns and revealed a coinfection rate of 23.8% for SARS-CoV-2, often in association with rhinovirus or influenza A. This study provides valuable data to understand post-pandemic viral interactions, which is imperative for public health interventions.

NSAIDs for early management of acute respiratory infections.

To review the rationale for and the potential clinical benefits of an early approach to viral acute respiratory infections with NSAIDs to switch off the inflammatory cascade before the inflammatory process becomes complicated. It has been shown that in COVID-19 as in other viral respiratory infections proinflammatory cytokines are produced, which are responsible of respiratory and systemic symptoms. There have been concerns that NSAIDs could increase susceptibility to SARS-CoV-2 infection or aggravate COVID-19. However, recent articles reviewing experimental research, observational clinical studies, randomized clinical trials, and meta-analyses conclude that there is no basis to limit the use of NSAIDs, which may instead represent effective self-care measures to control symptoms. The inflammatory response plays a pivotal role in the early phase of acute respiratory tract infections (ARTIs); a correct diagnosis of the cause and a prompt therapeutic approach with NSAIDs may have the potential to control the pathophysiological mechanisms that can complicate the condition, while reducing symptoms to the benefit of the patient. A timely treatment with NSAIDs may limit the inappropriate use of other categories of drugs, such as antibiotics, which are useless when viral cause is confirmed and whose inappropriate use is responsible for the development of resistance.

THE ISSUE OF INFECTIOUS DISEASE INCIDENCE AMONG MEDICAL STUDENTS

Introduction. The training of future medical professionals involves not only development of skills and professional background, but also maintaining a sufficient health status; therefore the relevance of studying an incidence of infectious pathologies in medical students is exceptionally important. The purpose of the study is to investigate, analyze, and compare incidence of some infectious diseases among medicine students. Materials and methods. We utilized various research methods including analysis of scientific sources, synthesis and comparison of studies by other researchers, surveys, observations, interviews, and statistical data on the incidence of infectious diseases in Ukraine and worldwide. Additionally, we conducted a poll among first-year students of the medical faculty at Vinnytsia National Pirogov Memorial Medical University using Google Forms to gather data on the incidence of respiratory and digestive system infections. The study revealed that approximately 65% of the surveyed students had experienced coronavirus disease, mostly in a mild form. Among acute respiratory viral infections, flu (55.3%), sore throat (31.3%), and rhinopharyngitis (21.3%) were the most common (79.1%) among medical students. About 74% of respondents reported no chronic diseases of the upper and lower respiratory tract, while the rest mentioned conditions such as allergic rhinitis (10%), chronic tonsillitis (10%), chronic pharyngitis (3.4%), and vocal cord diseases (2%). In terms of infectious pathologies of the digestive system, food poisoning of unspecified etiology (33.3%) and viral intestinal infections (11.7%) were the most prevalent. Conclusion. The relevance of the issue of infectious disease incidence among medical students necessitates further investigation and analysis to identify contributing factors, develop monitoring methods, and promote healthy lifestyles to maintain optimal health status.